Arbutus Biopharma Corp (ABUS): Net earnings per share for the last 12 months

Symbol and logo of brand Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma (ABUS) develops high-margin hepatitis B drugs with global market potential. The 12-month EPS trend on this GURU.Markets chart demonstrates financial resilience, while the 1.12 metric confirms current levels. The business model relies on outsourced manufacturing to minimize capital expenditures. Market confidence is sustained by a reputable management team that effectively protects intellectual property.

ABUS (Arbutus Biopharma) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/15/2026

Summary analytical data breakdowns for Tekmira Pharmaceuticals (ABUS)

- stock price and consensus target price:
- stock exchange capitalization data:
General company analysis:Arbutus Biopharma Corporation (ABUS)
Manufactured products of Arbutus

The investment attractiveness of Arbutus Biopharma (ABUS) is based on the scientific value of its RNA platform for hepatitis B therapy, making the monitoring of real business returns critically important. Analyzing this 12-month net income per share chart, an investor can see the final profit distributed per share, which allows for an assessment of capital efficiency regardless of share dilution and determines the fundamental stability of the company.